All In MedTech

FDA Clearance Tracker · P990009-S037

FLOSEAL HEMOSTATIC MATRIX

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 27, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 27, 2014

Approved

Time to decision

355 days

Received Jun 6, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P990009-S037
Device name
FLOSEAL HEMOSTATIC MATRIX
Applicant location
Round Lake, IL
Received
Jun 6, 2013
Decided
May 27, 2014
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P990009

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code LMF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR REVISED LABELING TO INCLUDE A SUMMARY OF THE NASSO ET AL. CLINICAL TRIAL, UPDATE THE DEVICE DESCRIPTION, AND EXTEND THE THROMBIN RECONSTITUTION PERIOD.

Source documents

Other decisions for Baxter Healthcare Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.